Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TTNP | TITAN PHARMACEUTICALS INC | 2025-10-01 18:59:54 | 5.91 | 1.3 | 28.2 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TTNP | 0000910267 | TITAN PHARMACEUTICALS INC | US8883147055 | 549300NOUZGB2ZNVJ794 | 943171940 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 400 OYSTER POINT BLVD | SAN FRANCISCO | CA | 94080 | UNITED STATES | US | 6502444990 | 400 OYSTER POINT BLVD, SAN FRANCISCO, CA, 94080 | 400 OYSTER POINT BLVD, SAN FRANCISCO, CA, 94080 | — | Pharmaceuticals | — | David Lazar | 14 | http://titanpharm.com | 3,700,000 | 1,330,234 | 1,330,234 | Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group. | 2025-10-30 17:55:27 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 3,700,000 | -3,600,000 | -49.3151 | 914,234 | 0 | 0 |
| 2023 | 7,300,000 | -800,000 | -9.8765 | 914,234 | -14,102,061 | -93.9117 |
| 2022 | 8,100,000 | -17,500,000 | -68.3594 | 15,016,295 | 2,976,874 | 24.7261 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Seow Gim Shen | Chief Executive Officer | 2024 | 0 | 0 | 0 | — | 0 | 0 |
| Katherine Beebe | Chief Operating Officer, President | 2024 | 523,705 | 192,500 | 0 | — | 43,421 | 759,626 |
| Chay Weei Jye | Chief Executive Officer | 2024 | 0 | 0 | 0 | — | 0 | 0 |
| Brynner Chiam | Principal Executive Officer, Principal Financial Officer | 2024 | 0 | 0 | 0 | — | 0 | 0 |
| Brynner Chiam | Principal Executive Officer, Principal Financial Officer | 2023 | 0 | 0 | 0 | — | 0 | 0 |
| Fiscal Year | Employee Count |
|---|---|
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 11 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | — | 184,000 | 557,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | — | 1,913,000 | 4,758,000 |
| General And Administrative Expenses | 4,557,000 | 5,548,000 | 6,034,000 |
| Operating Expenses | 4,557,000 | 7,461,000 | 10,792,000 |
| Operating Income | -4,557,000 | -7,277,000 | -10,235,000 |
| Net Income | -4,706,000 | -5,569,000 | -10,206,000 |
| Earnings Per Share Basic | -5.23 | -7.41 | — |
| Earnings Per Share Diluted | -5.23 | -7.41 | -0.76 |
| Weighted Average Shares Outstanding Basic | 899,000 | 752,000 | — |
| Weighted Average Shares Outstanding Diluted | 899,000 | 752,000 | 13,428,947 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 2,831,000 | 6,760,000 | 2,937,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | — | 46,000 | 36,000 |
| Inventories | — | 0 | 106,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 2,923,000 | 8,018,000 | 3,603,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | 5,000 | 224,000 |
| Other Assets Non Current | — | — | 48,000 |
| Total Assets Non Current | 0 | 68,000 | 455,000 |
| Total Assets | 2,923,000 | 8,086,000 | 4,058,000 |
| Accounts Payable | 202,000 | 348,000 | 695,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 483,000 | 1,444,000 | 2,630,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 0 | 0 | 65,000 |
| Total Liabilities | 483,000 | 1,444,000 | 2,695,000 |
| Common Stock | 1,000 | 1,000 | 15,000 |
| Retained Earnings | -396,536,000 | -391,830,000 | -386,261,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 2,440,000 | 6,642,000 | 1,363,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 5,000 | 112,000 | 196,000 |
| Share Based Compensation Expense | — | 1,013,000 | 947,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | -46,000 | 10,000 | -76,000 |
| Change In Inventories | -1,000,000 | — | -187,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -145,000 | -476,000 | -751,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -3,880,000 | -7,092,000 | -8,183,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | — | 2,000 | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | — | 732,000 | — |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -62,000 | 10,000,000 | 4,984,000 |
| Change In Cash | — | 3,640,000 | — |
| Cash At End Of Period | 2,831,000 | 6,760,000 | 2,937,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 13,000 | 21,000 | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -5.23 | -7.41 | — |
| Price To Earnings Ratio | -0.6233 | -1.1134 | — |
| Earnings Growth Rate | -29.4197 | — | — |
| Price Earnings To Growth Ratio | 0.0212 | — | — |
| Book Value Per Share | 2.7141 | 8.8324 | — |
| Price To Book Ratio | 1.2011 | 0.9341 | — |
| Ebitda | -4,701,000 | -5,457,000 | -10,010,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | — | -107,000 | 0 |
| Free Cash Flow | — | -6,985,000 | -8,183,000 |
| Return On Equity | -1.9287 | -0.8385 | -7.4879 |
| One Year Beta | -0.3576 | 0.2713 | 0.8365 |
| Three Year Beta | 0.513 | 0.7371 | 0.6256 |
| Five Year Beta | 0.5342 | 0.6605 | 0.5632 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Ben-Tzvi Avraham | Director | 2025-10-01 | 3,313 | D | 0 |
| Ben-Tzvi Avraham | Director | 2025-10-01 | 1,250 | D | 0 |
| Choong Choon Hau | 10% owner | 2024-03-18 | 54,132 | A | 3,802,100 |
| Choong Choon Hau | 10% owner | 2024-03-18 | — | D | 0 |
| Ben-Tzvi Avraham | Director | 2023-10-25 | 16,250 | A | 66,250 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| OSAIC HOLDINGS, INC. | 2025-06-30 | 40 | 10 | 4 |
| Cape Investment Advisory, Inc. | 2025-06-30 | 4 | 1 | 4 |
| MORGAN STANLEY | 2025-06-30 | 8 | 2 | 4 |
| RAYMOND JAMES FINANCIAL INC | 2025-06-30 | 4 | 1 | 4 |
| CITADEL ADVISORS LLC | 2025-06-30 | 50,690 | 12,069 | 4.2 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | Avantis Emerging Markets Equity ETF | AVEM | 712,000 | 90,075.67 | 0.0007 |
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | G Class | AVENX | 20,000 | 2,530.22 | 0.0004 |
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | Institutional Class | AVEEX | 20,000 | 2,530.22 | 0.0004 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Select Shares | VSEMX | 4,103 | 17,232.6 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Plus Shares | VEMPX | 4,103 | 17,232.6 | 0.0 |